Diplomat to dispense Ocrevus, Dupixent
FLINT, Mich. — Diplomat Pharmacy this week announced that it would be dispensing two drugs, one of which is limited-distribution. The company will be dispensing Dupixent (dupilumab) and the limited-distribution Ocrevus (ocrelizumab).
Dupixent, a treatment for moderate-to-severe atopic dermatitis, was co-developed by Sanofi and Regeneron, and is administered through subcutaneous injection.
“Moderate-to-severe atopic dermatitis is a debilitating, life-altering disease with very limited treatment options,” Diplomat president Paul said. “We are thrilled to offer this new option for patients with unmet needs.”
Ocrevus is a treatment for relapsing multiple sclerosis and primary progressive multiple sclerosis, the former of which is the most common form of the disease. One-in-10 people have primary progressive multiple sclerosis. Genentech and Roche developed the drug.
“We are excited to make this highly anticipated treatment option available to patients in need,” Urick said. “Ocrevus can reduce the burden of multiple sclerosis and give patients hope.”
No comments found